tolerability profile

Related by string. tolerability profiles * Tolerability : safety tolerability pharmacokinetics . efficacy tolerability . safety tolerability pharmacokinetic . favorable tolerability . tolerability pharmacokinetics / profiles . Profiles . PROFILE . PROFILES : Quote Profile Research . Profile Research Stock Buzz . #.T Quote Profile Research . Citigroup CN Quote Profile * *

Related by context. All words. (Click for frequent words.) 80 tolerability 77 pharmacokinetic profile 74 tolerability profiles 72 oral bioavailability 71 pharmacodynamic profile 71 antiviral activity 70 pharmacokinetic properties 70 pharmacokinetic profiles 70 favorable tolerability 69 efficacy 69 pharmacodynamic properties 68 anti leukemic 68 antitumor activity 68 ganetespib 68 analgesic efficacy 67 teriflunomide 67 potent antiviral 66 efficacy tolerability 66 dosing regimen 66 pharmacokinetics 66 pharmacokinetic 66 GLYX 66 dosing regimens 66 bronchodilation 66 antiviral efficacy 66 ISIS # 66 pharmacokinetic characteristics 65 favorable pharmacokinetic profile 65 pharmacodynamic 65 nebulized formoterol fumarate 65 oral prodrug 65 dose regimens 65 pomalidomide 64 vidofludimus 64 PRT# 64 pharmacodynamics PD 64 monotherapy 64 posaconazole 64 Zoraxel 64 active comparator 64 administered subcutaneously 64 decitabine 64 PRTX 64 bendamustine 64 Phase 1b trial 64 CYT# 64 immunogenicity 64 ADAGIO study 64 Bezielle 63 systemic absorption 63 oral dosing 63 tipranavir 63 forodesine 63 CIMZIA ™ 63 Ophena TM 63 ZYBRESTAT 63 CIMZIA TM 63 tiotropium 63 Phase 2a trial 63 PXD# 63 pharmacokinetics PK 63 preclinical efficacy 63 oral FTY# 63 axitinib 63 pharmacokinetic PK 63 preclinical studies 63 SCH # 63 Tolerability 63 riociguat 63 APTIVUS 63 prucalopride 63 oral formulation 63 JANUVIA 62 orally bioavailable 62 GFT# 62 Azedra 62 Traficet EN 62 dosage regimens 62 ORMD 62 viral kinetic 62 INCB# [002] 62 tanespimycin 62 ACTEMRA TM 62 torezolid phosphate 62 mcg dose 62 pitavastatin 62 rFIXFc 62 pertuzumab 62 amrubicin 62 enzastaurin 62 LY# [003] 62 Serdaxin 62 RDEA# 62 INCB# [001] 62 antiviral potency 62 neuroprotective properties 62 safety tolerability pharmacokinetic 62 chlorambucil 62 edoxaban 62 Preclinical studies 62 zalutumumab 62 oral rivaroxaban 62 mg dose 62 NGX# 62 CoFactor 62 #mg dose [001] 62 pharmacokinetic studies 62 salmeterol fluticasone 62 ARCOXIA 61 PEG Interferon lambda 61 azacitidine 61 diabetic neuropathic pain 61 placebo controlled studies 61 milatuzumab 61 pharmacodynamic PD 61 pharmacodynamics 61 adalimumab 61 Perforomist TM Inhalation Solution 61 BAL# [002] 61 melphalan prednisone 61 Zerenex 61 ELACYT 61 CR# vcMMAE 61 LEVADEX 61 Perforomist ™ Inhalation Solution 61 ENMD # 61 ACTEMRA 61 Phase 2a clinical 61 AZILECT R 61 tocilizumab 61 Phase 2b study 61 reactogenicity 61 Carfilzomib 61 DU #b 61 PEG SN# 61 phase Ib 61 Tyrima 61 SEROQUEL XR 61 sorafenib Nexavar 61 vivo efficacy 61 RAPAFLO 61 pharmacokinetic PK profile 61 elagolix 61 VA# [002] 61 oral diclofenac 61 CaPre TM 61 placebo controlled clinical trials 61 delafloxacin 61 mycophenolate mofetil 61 Archexin 61 highly immunogenic 61 clinical trials alitretinoin 61 eculizumab 61 clinically meaningful efficacy 61 ritonavir boosted 61 fluticasone furoate 61 PCK# 61 preclinical models 61 LT NS# 61 sunitinib 60 RoACTEMRA 60 anticancer activity 60 apremilast 60 fondaparinux 60 clinical trials Multikine 60 picoplatin 60 vandetanib 60 Protelos 60 temsirolimus 60 ULORIC 60 cardiac toxicity 60 PREZISTA r 60 CANCIDAS 60 Phase Ib 60 Locteron 60 Triolex 60 Alpharadin 60 active moiety 60 heavily pretreated 60 maximally tolerated dose 60 alvimopan 60 visilizumab 60 LEXIVA r 60 Pegasys ® 60 Phase IIa trial 60 liposomal formulation 60 Sym# 60 RLY# 60 Vidofludimus 60 polymerase inhibitor 60 dose cohorts 60 TRIOLEX 60 aclidinium 60 docetaxel Taxotere 60 MAP# 60 dosing schedules 60 MGCD# [002] 60 obatoclax 60 tolvaptan 60 ciclesonide 60 S/GSK# 60 INC# 60 solithromycin 60 viral kinetics 60 linear pharmacokinetics 60 Aclidinium 60 Elacytarabine 60 investigational oral 60 HuMax EGFr 60 pegylated interferons 60 glatiramer acetate 60 paliperidone ER 60 eltrombopag 60 investigational compound 60 aripiprazole Abilify 60 CA4P 60 bosentan 60 tiotropium bromide 60 LEXIVA 60 regorafenib 60 mapatumumab 60 NVA# 60 ProSavin 60 XmAb# 60 subcutaneous formulation 60 iclaprim 60 tapentadol ER 60 inecalcitol 60 nitazoxanide 60 seliciclib 60 antitumor effects 60 tolerated dose MTD 60 inhaled corticosteroid ICS 60 CTAP# Capsules 60 oral ridaforolimus 60 elacytarabine 60 ibandronate 60 phase IIb clinical 60 tivozanib 60 DDP# 60 pegylated liposomal doxorubicin 60 TOLAMBA 60 dosed orally 60 otelixizumab 60 Phase Ib study 60 CRx 60 tipifarnib 60 Anthim 59 preclinically 59 FTY# fingolimod 59 RSD# 59 teduglutide 59 heavily pretreated patients 59 insulin detemir 59 sitagliptin 59 JAK inhibitor 59 subcutaneously administered 59 Multimeric 59 CYCLOSET 59 placebo controlled trials 59 radezolid 59 Xanafide 59 Genz # 59 dose limiting toxicities 59 xenograft models 59 safinamide 59 mg QD 59 indibulin 59 Golimumab 59 nonclinical studies 59 inhibitor RG# 59 Targretin 59 IDX# 59 Dasatinib 59 nab paclitaxel 59 SEROQUEL 59 Phase 1b 59 Virulizin ® 59 antithrombotic 59 Pharmacokinetic 59 neurotoxicity 59 intravenous dosing 59 LCP Tacro 59 orally administered inhibitor 59 ARIKACE 59 selective modulator 59 PS# [001] 59 gemcitabine 59 BAY #-# 59 varespladib 59 DAVANAT 59 pharmacodynamic effects 59 hour bronchodilation 59 lomitapide 59 INT# [002] 59 febuxostat 59 tecarfarin 59 pioglitazone 59 HuMax CD# 59 LDL lowering 59 bortezomib 59 VAPRISOL 59 combinability 59 FOSRENOL R 59 GRN#L 59 ADX# 59 ATACAND 59 Zavesca R 59 dalbavancin 59 interferon alfa 2b 59 AEGR 59 HGS# 59 mTOR inhibitor 59 retapamulin 59 SPIRIVA HandiHaler 59 Interferon alpha 59 Laquinimod 59 anti amnesic 59 INGN 59 tezampanel 59 MGCD# [001] 59 Prulifloxacin 59 RE SURGE 59 Hematologic toxicity 59 virologic response 59 RG# [001] 59 bioavailability 59 elotuzumab 59 fluticasone salmeterol 59 anastrozole 59 FOLPI 59 placebo controlled clinical 59 HQK 59 MEK inhibitors 59 uric acid lowering 59 KRN# 59 administered orally 59 Valdoxan 59 telcagepant 59 Amrubicin 59 AZILECT ® 59 Phase 2a 59 glucose lowering 59 novel histone deacetylase 59 CINQUIL 59 demonstrated antitumor activity 59 leukotriene receptor antagonists 59 SYMBICORT 59 protease inhibitor PI 59 Visipaque 59 YONDELIS 59 MERLIN TIMI 59 FTY# 59 fosamprenavir 59 plus ribavirin 59 Combination therapy 59 Phase 1a 59 Pharmacokinetics PK 59 DACH platinum 59 Dapagliflozin 59 trodusquemine 59 XL# SAR# 59 evaluating tivozanib 59 antitumor efficacy 59 Phase 1b clinical 59 lanthanum carbonate 59 zileuton 59 ADVANCE PD 59 Pimavanserin 59 teriparatide 59 angiotensin receptor blocker ARB 59 Rebif ® 59 multi kinase inhibitor 59 idraparinux 59 iniparib 59 Telmisartan 59 COPEGUS 59 limiting toxicity 59 subcutaneous SC 59 phase IIa clinical 59 pegylated interferon alfa 58 cannabinor 58 SNRI 58 CIMZIA TM certolizumab pegol 58 Valortim 58 interferon alfa 58 Phase 2b trial 58 desvenlafaxine succinate 58 IRX 2 58 urocortin 2 58 darunavir ritonavir 58 XGEVA 58 immunogenic 58 Welchol 58 R#/MEM # 58 NP2 Enkephalin 58 Adalimumab 58 TAXUS VI 58 Vandetanib 58 ONGLYZA 58 fluvastatin 58 coadministration 58 Seliciclib 58 PROMACTA 58 bifeprunox 58 ataluren 58 urate lowering 58 NPH insulin 58 doripenem 58 convenient dosing regimen 58 Chemophase 58 mg BID 58 sunitinib malate 58 pan HDAC inhibitor 58 DASISION 58 efficacious 58 secondary efficacy endpoints 58 ceftaroline 58 ARRY 58 topotecan 58 administered intranasally 58 BNC# 58 6R BH4 58 refractory gout 58 baminercept 58 #D#C# 58 pharmacokinetic parameters 58 ruxolitinib 58 Neurodex 58 talactoferrin 58 lacosamide 58 overlapping toxicities 58 telbivudine 58 efficacy endpoints 58 pharmacokinetic PK study 58 TYGACIL 58 PSN# [002] 58 TREDAPTIVE 58 pazopanib 58 Thiovir 58 candesartan cilexetil 58 dose proportionality 58 TriRima 58 caspofungin 58 NEVO ™ 58 sunitinib Sutent ® 58 HMG CoA reductase inhibitors 58 Menerba 58 alvespimycin 58 pramlintide metreleptin combination 58 docetaxel Taxotere ® 58 bicifadine 58 ceftazidime 58 relapsed myeloma 58 Epanova 58 Phase Ib clinical 58 Zenvia 58 galiximab 58 leucovorin 58 plus gemcitabine 58 oral Xeloda 58 dexamethasone Decadron 58 Phase IIa clinical 58 IMA# 58 SPRYCEL 58 Capesaris 58 Afatinib 58 pharmacokinetic equivalence 58 CBLC# 58 Tarceva TM 58 FOLFIRI 58 ZOLINZA 58 LCP AtorFen 58 eniluracil 58 deferiprone 58 relapsed SCLC 58 platelet inhibitor 58 BRAF inhibitor 58 dose escalation trial 58 intravenously administered 58 FOSRENOL ® 58 tigecycline 58 LIALDA 58 1mg dose 58 erlotinib Tarceva ® 58 LEP ETU 58 RAPAFLO R 58 Apoptone 58 Panzem R 58 fluconazole 58 inhaled iloprost 58 ascending doses 58 canakinumab 58 RGB # 58 OXi# 58 cidofovir 58 carboplatin paclitaxel 58 EOquin TM 58 IMC A# 58 oxymorphone ER 58 dose regimen 58 eprotirome 58 Perforomist Inhalation Solution 58 alfa 2a 58 HGS ETR1 58 rHuPH# 58 ZOMIG 58 hGH CTP 58 mg doses 58 TNF antagonists 58 APRISO 58 IMGN# 58 PEG PAL 58 renal toxicity 58 Ribavirin 58 AZILECT 58 Phase IIb trials 58 abatacept 58 randomized Phase III 58 plasma kallikrein inhibitor 58 CaPre ™ 58 itraconazole 58 pharmacokinetics pharmacodynamics 58 intermittent dosing 58 dasatinib 58 convenient dosing regimens 58 Resolute DES 58 VQD 58 MoxDuo IR 58 safety tolerability 58 Debio 58 beclomethasone dipropionate 58 estramustine 58 CCX# 58 Rasagiline 58 Combo Stent 58 Darinaparsin 58 Inhalation Solution 58 TORISEL 58 SRT# [003] 58 HDAC inhibitor 58 peginterferon alfa 2a 58 FOLFOX4 58 cariprazine 58 CLORETAZINE TM VNP#M 58 boosted protease inhibitor 58 telmisartan 58 temozolomide 58 immune modulating 58 clinically meaningful 58 mTOR inhibitors 58 deforolimus 58 immunomodulatory therapy 58 paclitaxel poliglumex 58 anti angiogenic 58 pemetrexed 57 OMNARIS HFA 57 antiarrhythmic 57 Pazopanib 57 Pemetrexed 57 indacaterol 57 QAB# 57 metaglidasen 57 insulin lispro 57 Imprime PGG 57 Allovectin 7 ® 57 docetaxel Taxotere R 57 dexpramipexole 57 AEG# 57 DXL# 57 Plicera 57 rNAPc2 57 Phase Ia 57 entinostat 57 abacavir lamivudine 57 LATUDA 57 SGS# 57 palonosetron 57 CGEN # 57 docetaxel chemotherapy 57 erlotinib 57 APTIVUS r 57 insulin degludec 57 EFAPROXYN 57 MoxDuo 57 Asentar 57 Tolvaptan 57 systemically administered 57 gemcitabine cisplatin 57 ACE inhibitor ramipril 57 Onconase 57 Icatibant 57 Tamibarotene 57 MICARDIS ® 57 Cethromycin 57 dose ritonavir 57 atacicept 57 NEXIUM 57 mg kg BID 57 phase 2a 57 Fludara 57 RAPTIVA 57 oral anticoagulant 57 ranolazine 57 certolizumab 57 TELCYTA 57 novel VDA molecule 57 vorinostat 57 etanercept 57 PDE4 inhibitors 57 afatinib 57 TRO# 57 anidulafungin 57 ospemifene 57 lopinavir r 57 Phase IIb clinical 57 PPAR gamma agonist 57 brivaracetam 57 pharmacokinetic interactions 57 Doxil ® 57 Cimzia TM 57 noninferiority 57 davunetide intranasal AL 57 adalimumab Humira 57 placebo controlled 57 TYKERB 57 vinorelbine 57 tenofovir emtricitabine 57 Taxotere R 57 dosing cohort 57 pegylated interferon alfa 2a 57 fosbretabulin 57 sapacitabine 57 budesonide 57 partial agonist 57 pegylated 57 ponatinib 57 romidepsin 57 Phase 2b clinical 57 Hyphanox 57 mGluR5 NAM 57 FOLPI regimen 57 QLT# 57 entecavir 57 Raptiva ® 57 Instanyl 57 oxaliplatin Eloxatin 57 ISENTRESS 57 antitumor effect 57 subcutaneous injections 57 erythropoietic 57 5 FU 57 cethromycin 57 dacarbazine 57 Synavive 57 Cotara 57 Forodesine HCl 57 MIRCERA 57 viral suppression 57 ProLindac 57 Copegus ribavirin 57 panitumumab Vectibix 57 Q#IR 57 Cancidas 57 oral antiviral 57 arzoxifene 57 biodistribution 57 Dabigatran etexilate 57 virus HCV protease inhibitor 57 TMC# [001] 57 neurologic progression 57 HGS ETR2 57 COPAXONE R 57 bavituximab 57 PHX# 57 optimal dosing 57 SCIg 57 gemcitabine Gemzar 57 cardioprotective effects 57 clevidipine 57 NXL# 57 mg/m2 dose 57 TREANDA 57 achieved statistical significance 57 CYPHER ® Stent 57 Preclinical studies suggest 57 lopinavir ritonavir 57 tezampanel NGX# 57 ACZ# 57 phase IIb study 57 ALB # 57 PRECiSE 57 Phenoptin 57 glargine 57 HCV protease 57 darunavir 57 Octreolin 57 echinocandin 57 retinoid 57 HspE7 57 Cimzia ® 57 REVLIMID 57 dosing 57 orally dosed 57 antiarrhythmic drug 57 mecamylamine 57 oral Hycamtin 57 Victoza R 57 reslizumab 57 OHR/AVR# 57 NATRECOR ® 57 cilengitide 57 paclitaxel eluting stents 57 TRV# [001] 57 CRMD# 57 Teriflunomide 57 daclizumab 57 olanzapine Zyprexa 57 omega interferon 57 lenalidomide dexamethasone 57 LY# [002] 57 Marqibo 57 limiting toxicity DLT 57 PF # [001] 57 Factor Xa inhibitor 57 Moxifloxacin 57 MORAb 57 plus dexamethasone 57 fluoroquinolone antibiotic 57 huC# DM4 57 ANA# 57 INVEGA ® 57 pharmacokinetic pharmacodynamic 57 Engerix B 57 HIF PHI 57 proton pump inhibitor PPI 57 double blinded placebo 57 KAPIDEX 57 rALLy trial 57 Phase 2b clinical trials 57 azilsartan medoxomil 57 TMC# [002] 57 atypical antipsychotic 57 bevirimat 57 anti EGFR antibody 57 NOXAFIL Oral Suspension 57 MAGE A3 ASCI 57 allopurinol 57 Rivaroxaban 57 imatinib therapy 57 demonstrated clinically meaningful 57 Lantus R 57 AAG geldanamycin analog 57 bosutinib 57 MGd 57 surrogate endpoint 57 VELCADE 57 neratinib 57 adecatumumab 57 complete cytogenetic response 57 EDEMA3 trial 57 receptor inhibitor 57 panitumumab 57 AEZS 57 HyQ 57 Aplidin 57 Cloretazine R VNP#M 57 MDV# 57 dose escalation 57 NOXAFIL 57 lenalidomide Revlimid R 57 vernakalant 57 velafermin 56 carboplatin 56 ketorolac 56 relapsed MM 56 rindopepimut 56 latrepirdine 56 antiepileptic drug 56 Omacetaxine mepesuccinate 56 PMX # 56 dosing frequency 56 pharmacodynamic profiles 56 plus prednisone 56 Mycamine 56 pimecrolimus 56 pramlintide 56 DCCR 56 vismodegib 56 Elitek 56 CYPHER R Sirolimus eluting 56 bronchodilatory 56 Firazyr 56 metformin sulfonylurea 56 GAMMAGARD 56 placebo controlled Phase 56 NeuroSTAT ® 56 nilotinib 56 rivaroxaban 56 mertansine 56 REMICADE ® 56 Taxotere ® 56 Irinotecan 56 M6G 56 Aptivus 56 Oral NKTR 56 hyperphenylalaninemia HPA due 56 angiogenesis inhibitor 56 DP b# 56 lurasidone 56 LibiGel ® 56 AVONEX ® 56 docetaxel 56 Ceflatonin 56 TG# [003] 56 micafungin 56 sorafenib 56 MabCampath 56 lucinactant 56 pioglitazone HCl 56 veltuzumab 56 Phase IIa 56 randomized controlled clinical trials 56 basal bolus regimen 56 methylnaltrexone 56 pharmacologic 56 INCB# [003] 56 dimebon 56 acamprosate 56 RSD# oral 56 anticancer agent 56 raltegravir 56 AGILECT R 56 alicaforsen enema 56 antidepressant efficacy 56 plus COPEGUS 56 Phase IIIb clinical 56 Arikace 56 Focalin XR 56 mucosal healing 56 aripiprazole 56 Tezampanel 56 glycopyrrolate 56 ascending dose 56 VIDAZA 56 oral antidiabetic 56 DOXIL 56 trabectedin 56 anakinra 56 granisetron 56 Entereg R 56 anti emetic therapy 56 CLL8 56 ribavirin therapy 56 VELCADE melphalan 56 statistically significant efficacy 56 Tocilizumab 56 dose cohort 56 oritavancin 56 CG# [003] 56 rFVIIa 56 LIVALO 56 dose proportional pharmacokinetics 56 Pegasys peginterferon alfa 2a 56 mixed dyslipidemia 56 ancrod 56 favorable pharmacokinetic 56 FUSILEV enhances 56 Femara letrozole 56 LDL cholesterol lowering 56 INVEGA R 56 biologic therapy 56 certolizumab pegol 56 sulodexide 56 DexaSite 56 QNEXA 56 pegfilgrastim 56 intranasal delivery 56 SILENOR TM 56 depsipeptide 56 octreotide LAR 56 beta 1a 56 ATL/TV# 56 tasimelteon 56 infrequent dosing 56 primary hypercholesterolemia 56 QVAR ® 56 cystinosis patients 56 budesonide formoterol 56 TNF inhibitor 56 thalidomide Thalomid 56 generation purine nucleoside 56 non selective NSAIDs 56 calcitonin 56 standard chemotherapy regimen 56 INVANZ 56 custirsen 56 Keppra ® 56 tolterodine ER 56 headache nasopharyngitis 56 Aliskiren 56 LibiGel Phase III 56 Zentase 56 antitumor 56 colesevelam HCl 56 Aptivus ® 56 Denufosol 56 LEVAQUIN ® 56 Multaq R 56 vitro cytotoxicity 56 relapsing remitting multiple sclerosis 56 dronedarone 56 Phase #/#a 56 #mg dose [002] 56 TTF Therapy 56 daunorubicin 56 peginterferon alpha 2a 56 Diovan HCT 56 mcg kg 56 EURIDIS 56 alkylating agent 56 ramelteon 56 #mg BID [003] 56 albinterferon alfa 2b 56 dosage regimen 56 ocrelizumab 56 miconazole 56 immunomodulator 56 vitro studies 56 cabazitaxel 56 factor Xa inhibitor 56 HuLuc# 56 pramipexole 56 Victoza ® 56 microplasmin 56 cediranib 56 imatinib resistant 56 Aflibercept 56 intravenous bisphosphonates 56 selective antagonist 56 oxcarbazepine 56 TAFA# 56 IFN alfa 56 interferon gamma 1b 56 zoledronic acid 56 Onbrez Breezhaler 56 ToGA 56 peginterferon alfa 2b 56 ofatumumab 56 CRLX# 56 paricalcitol 56 UPLYSO 56 YONDELIS R 56 bicalutamide 56 laquinimod 56 casopitant 56 orBec 56 TPI ASM8 56 naproxcinod 56 Lialda 56 insulin sensitizing 56 rBChE 56 thromboembolic events 56 tamibarotene 56 dabigatran etexilate 56 radiation sensitizer 56 Etoposide 56 valsartan 56 idarubicin 56 celgosivir 56 glycemic control 56 Valortim ® 56 Ranolazine 56 enfuvirtide 56 Empatic 56 Eltrombopag 56 oral olanzapine 56 PDE4 inhibitor 56 tesmilifene 56 Campath alemtuzumab 56 Monotherapy 56 DAPT 56 aflibercept 56 statin monotherapy 56 β blockers 56 Tanespimycin 56 multiple ascending dose 56 OncoVEX GM CSF 56 potency selectivity 56 Peginterferon 56 Durezol 56 GLPG# 56 IV bisphosphonates 56 interferon beta therapy 56 nucleoside analogs 56 Mipomersen 56 oral deforolimus 56 metreleptin 56 KNS #

Back to home page